Nabriva therapeutics plc (NBRV)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities
Net loss

-85,806

-82,764

-90,544

-125,574

-121,655

-114,780

-106,217

-75,661

-72,475

-74,356

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other income/expense, net

-660

40

-146

-268

-447

-362

-152

272

1,217

1,371

77

-241

-1,654

-996

0

0

0

Non-cash interest income

-50

-22

-126

-123

-42

-45

0

0

0

-

-

50

38

52

0

0

0

Non-cash interest expense

293

519

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization expense

374

396

281

493

502

510

528

545

489

432

356

283

264

233

0

0

0

Amortization of right-of-use assets

280

374

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

9,606

9,748

9,586

6,871

5,817

5,154

4,628

4,867

6,292

5,732

5,100

4,016

2,649

2,545

0

0

0

Deferred income taxes

-

-

-

-

-

-

-

-

-

1,410

1,044

-1,446

-598

-794

0

0

0

Other, net

0

-

-

-1

28

14

-4

21

39

131

112

105

86

1

0

0

0

Changes in operating assets and liabilities:
Increase in long-term receivables

-

-50

288

282

10

3

0

0

0

-

-

-28

-20

-10

0

0

0

Increase in accounts receivable, net and other receivables and prepaid expenses

-2,906

-2,582

-2,242

-4,041

-481

-1,139

4,138

-582

629

223

0

0

0

-

-

-

-

Increase in inventory

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in other receivables

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Increase/(decrease) in accounts payable

-5,529

1,310

-1,535

-1,074

2,746

-2,969

-1,520

-4,631

-617

2,585

2,483

5,689

-829

-383

0

0

0

Decrease in accrued expenses and other liabilities

-619

-3,209

1,052

1,778

2,679

5,742

-237

-464

-4,706

-3,778

-1,621

-972

3,160

6,034

0

0

0

Increase/(decrease) in other non-current liabilities

-88

-172

-68

-24

9

61

110

111

112

96

38

33

22

24

0

0

0

Increase/(decrease) in income tax liabilities

-113

-74

-153

-256

-375

58

259

327

460

-1

0

0

0

-

-

-

0

Net cash used in operating activities

-79,375

-71,892

-78,636

-81,111

-77,009

-72,723

-74,574

-72,489

-71,003

-69,348

0

0

0

-

-

-

-

Cash flows from investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Purchases of plant and equipment and intangible assets

91

61

117

118

111

229

241

1,105

1,308

1,173

1,288

532

561

603

0

0

0

Changes in restricted cash

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of property, plant and equipment

-

-

-

-

-

-

-

-

-

2

0

0

0

-

-

-

-

Proceeds from sales of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Proceeds from sales of available-for-sale securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in investing activities

353

331

-98

-19,378

-4,486

-4,604

-3,987

31,700

39,612

49,749

0

0

0

-

-

-

-

Cash flows from financing activities
Proceeds from at-the-market facility

18,120

27,944

24,624

15,027

14,809

24,219

0

0

0

-

-

-

-

-

-

-

-

Repayments of long-term borrowings

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from long-term debt, net of issuance costs

-

-

-

-

-

23,545

535

410

188

228

0

0

0

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

83

109

43

250

269

0

0

0

Equity transaction costs

2,433

2,359

777

4,279

4,622

4,841

6,433

7,585

7,200

8,092

0

0

0

-

-

-

-

Net cash provided by (used in) financing activities

16,177

56,075

57,007

84,133

83,543

92,923

66,886

95,681

92,449

72,219

0

0

0

-

-

-

-

Effects of foreign currency translation on cash and cash equivalents

-815

-106

-275

-231

-447

-362

0

0

0

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-63,660

-15,592

-22,002

-16,587

1,601

15,234

0

0

0

-

-

-

-

-

-

-

-

Effects of foreign currency translation on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Effects of foreign currency translation on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-2,287

-

0

0

0

Supplemental disclosure of cash flow information:
Interest paid

3,099

2,560

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from at-the-market facility in accounts receivable, net and other receivables

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity transaction costs incurred in prior periods and paid in current period

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Equity transaction costs included in accounts payable and accrued expenses

752

555

393

499

-286

120

0

0

0

-

-

-

-

-

-

-

-